Mechanisms of Glioma-Associated Neovascularization

被引:343
作者
Hardee, Matthew E. [2 ]
Zagzag, David [1 ,3 ,4 ,5 ]
机构
[1] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Radiat Oncol, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA
[4] NYU, Sch Med, Div Neuropathol, New York, NY 10016 USA
[5] NYU, Sch Med, Microvasc & Mol Neurooncol Lab, New York, NY 10016 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; HIGH-GRADE GLIOMA; INHIBITS TUMOR-GROWTH; PRIMARY BRAIN-TUMORS; STEM-LIKE CELLS; PROGENITOR CELLS; MALIGNANT GLIOMA; TIE2-EXPRESSING MONOCYTES; VASCULOGENIC MIMICRY;
D O I
10.1016/j.ajpath.2012.06.030
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Glioblastomas (GBMs), the most common primary brain tumor in adults, are characterized by resistance to chemotherapy and radiotherapy. One of the defining characteristics of GBM is an abundant and aberrant vasculature. The processes of vascular co-option, angiogenesis, and vasculogenesis in gliomas have been extensively described. Recently, however, it has become clear that these three processes are not the only mechanisms by which neovascularization occurs in gliomas. Furthermore, it seems that these processes interact extensively, with potential overlap among them. At least five mechanisms by which gliomas achieve neovascularization have been described: vascular co-option, angiogenesis, vasculogenesis, vascular mimicry, and (the most recently described) glibblastoma-endothelial cell transdifferentiation. We review these mechanisms in glioma neovascularization, with a particular emphasis on the roles of hypoxia and glioma stem cells in each process. Although some of these processes are well established, others have been identified only recently and will need to be further investigated for complete validation. We also review strategies to target glioma neovascularization and the development of resistance to these therapeutic strategies. Finally, we describe how these complex processes interlink and overlap. A thorough understanding of the contributing molecular processes that control the five modalities reviewed here should help resolve the treatment resistance that characterizes GBMs. (Am J Pathol 2012, 181:1126-1141; http://dx.doi.org/10.1016/j.ajpath.2012.06.030)
引用
收藏
页码:1126 / 1141
页数:16
相关论文
共 101 条
[1]   Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes [J].
Aghi, Manish ;
Cohen, Kenneth S. ;
Klein, Rachael J. ;
Scadden, David T. ;
Chioccra, E. Antonio .
CANCER RESEARCH, 2006, 66 (18) :9054-9064
[2]   HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α [J].
Arany, Zoltan ;
Foo, Shi-Yin ;
Ma, Yanhong ;
Ruas, Jorge L. ;
Bommi-Reddy, Archana ;
Girnun, Geoffrey ;
Cooper, Marcus ;
Laznik, Dina ;
Chinsomboon, Jessica ;
Rangwala, Shamina M. ;
Baek, Kwan Hyuck ;
Rosenzweig, Anthony ;
Spiegelman, Bruce M. .
NATURE, 2008, 451 (7181) :1008-U8
[3]   Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma [J].
Auf, Gregor ;
Jabouille, Arnaud ;
Guerit, Sylvaine ;
Pineau, Raphael ;
Delugin, Maylis ;
Bouchecareilh, Marion ;
Magnin, Noel ;
Favereaux, Alexandre ;
Maitre, Marlene ;
Gaiser, Timo ;
von Deimling, Andreas ;
Czabanka, Marcus ;
Vajkoczy, Peter ;
Chevet, Eric ;
Bikfalvi, Andreas ;
Moenner, Michel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (35) :15553-15558
[4]   Lack of specificity of endoglin expression for tumor blood vessels [J].
Balza, E ;
Castellani, P ;
Zulstra, A ;
Neri, D ;
Zardi, L ;
Siri, A .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (04) :579-585
[5]   Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].
Bao, Shideng ;
Wu, Qiulian ;
Sathornsumetee, Sith ;
Hao, Yueling ;
Li, Zhizhong ;
Hjelmeland, Anita B. ;
Shi, Oing ;
McLendon, Roger E. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
CANCER RESEARCH, 2006, 66 (16) :7843-7848
[6]   Therapeutic Targets in Malignant Glioblastoma Microenvironment [J].
Barcellos-Hoff, Mary Helen ;
Newcomb, Elizabeth W. ;
Zagzag, David ;
narayana, Ashwatha .
SEMINARS IN RADIATION ONCOLOGY, 2009, 19 (03) :163-170
[7]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[8]   Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches [J].
Beal, Kathryn ;
Abrey, Lauren E. ;
Gutin, Philip H. .
RADIATION ONCOLOGY, 2011, 6
[9]  
Blagosklonny MV, 2001, INT J ONCOL, V19, P257
[10]  
BREM S, 1972, J NATL CANCER I, V48, P347